Novo Nordisk Pharma sp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-02-18
Share capital
9,021,000.00 PLN
Activity description

Novo Nordisk Pharma Sp. z o.o. is the Polish entity of the global healthcare company Novo Nordisk, founded in Denmark in 1923. The company develops therapies for people with diabetes and other serious chronic diseases.

Registered address
ul. Krakowiaków 46, 02-255 Warszawa, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-15139-73037-GVBCC-33

Financials

Revenue history (in m)

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 47 days late). All were audited by a statutory auditor.

  • 202507/07/2026
  • 202412/06/2025
  • 202326/06/2024
  • 202206/06/2023
  • 202131/08/2022
  • 202001/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top <1%
City · Warszawa501 / 56,729
Top <1%
Voivodeship · Mazowieckie639 / 76,892
Top <1%
Country · Poland1,800 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 126.52mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD 7.86mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 118.29mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 64.81mMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Pharmaceutical products
  • Injection pens

Websites

The company has 4 websites. The company uses the Meta advertising pixel (Facebook, Instagram).

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 4 marks have expired or were not registered. The first mark was filed in 2001.

MarkNumberClassesStatusProtected until
i NovoSerwis Z.2460941, 2, 4, 5, 35, 36, 39, 42, 44Not registered –
@ NovoWebCafe Z.2460951, 2, 4, 5, 35, 36, 39, 42, 44Not registered –
@ novowebcafe Z.2401130, 44Expired –
i novoserwis Z.2401120, 44Expired –
MarkProtected until
i NovoSerwis –
@ NovoWebCafe –
@ novowebcafe –
i novoserwis –

Authorized Representatives

Cédric Jean-Paul Molla – Management Board Member
Sławomir Dominik Stachowicz age 51 – Attorney-in-fact (sole)
Jose Vinicius Garcia-Eboli age 45 – Management Board Member
Magdalena Edyta Paradzińska age 51 – Attorney-in-fact (sole)
Katarzyna Magdalena Kacperska – Management Board Member

Manner of representation

Each member of the management board is authorised to represent the company independently.

Ownership

OwnerSharesShare valueStake
Novo Nordisk Region Europe A/s
18,041$2,436,655.8699.9945%
Others
1$135.060.0055%

Beneficial owners

Person

Capital group

The company belongs to the Novo Nordisk A/S (Denmark) group. Its direct owner is Novo Nordisk Region Europe A/S (Denmark). The group has 6 companies, 4 of them abroad.

NameCountry
NNE A/SDenmark
Novo Nordisk Finance (Netherlands) B.V.Netherlands
Novo Nordisk Health Care AGSwitzerland
Novo Nordisk Service Centre (India) Private LimitedIndia

Bank accounts

Registered as a VAT taxpayer on 1996-07-01.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 1.1M

MSiG notices

Publication dateEvent
Oct 3, 2014Call to creditors

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Sanofi sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Gilead Sciences Poland sp. z o.o.
Reckitt Benckiser (Poland) S.A.
Abbott Medical sp. z o.o.
Pfizer Polska sp. z o.o.
Ipsen Poland sp. z o.o.
Magnapharm Poland sp. z o.o.
Vantage Trading sp. z o.o.

Change history

DateEvent
2018-11-16Address change
2018-02-07Address change
2015-02-13Share capital reduction
2008-12-18Address change
2008-12-01Address change

FAQ

Last updated: 2026-10-07